5th Exosome Based Therapeutic Development Summit

The 5th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.

This year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic.

This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP manufacturing of EVs for clinical applications, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization.

The 2023 conference covers:

Emerging standardized analytical strategies for optimized characterization, purification, and isolation to improve batch consistency and reproducibility towards successful scale-up. With insights from Rion, Astellas, OmniSpirant & Capricor Therapeutics
Key pre-clinical and clinical updates across a range of therapeutic areas, including the therapeutic potential of engineered exosomes in colorectal cancer and CNS disorders as well as novel exosome- based therapies for treating acute organ failures to address complex diseases with ShiftBio, EV Therapeutics & NurExone Biologic
The latest advancements of targeted delivery and therapeutic payloads by optimizing exosome loading for robust functional delivery, including the utilization of NK and stem-cell derived exosomes for the treatment of osteoarthritis and COVID-19 with StemXO, Cells for Cells & Capricor Therapeutics
The challenges of large-scale manufacturing by evaluating platform design and process development to ensure scalability for success in the clinic and towards commercialization with ExoBiologics, OrganiCell & Agele Therapeutics
Navigating the complex regulatory landscape across the drug development timeline to gain IND approval and advance into the clinic with insights from VivaZome Therapeutics, EV Therapeutics & The American College of Regenerative Medicine